Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism

References

• Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317–2337.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Cianferotti L, Beck-Peccoz P, et al. Rare diseases in clinical endocrinology: a taxonomic classification system. J Endocrinol Invest. 2015;38:193–259.
   PubMed Web of Science ®Google Scholar
• Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101:2273–2283.
   PubMed Web of Science ®Google Scholar
• Sikjaer T, Amstrup AK, Rolighed L, et al. PTH(1‐84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28:2232–2243.
   PubMed Web of Science ®Google Scholar
• Chu NN, Li XN, Chen WL, et al. Pharmacokinetics and safety of recombinant human parathyroid hormone (1‐34) (teriparatide) after single ascending doses in Chinese healthy volunteers. Pharmazie. 2007;62:869–871.
   PubMed Web of Science ®Google Scholar
• Natpara package insert. Available at: http://www.accessdata.fda- .gov/drugsatfda_docs/label/2015/125511s000lbl.pdf. [ Last accessed 22 June 2015]
   Google Scholar
• Conigrave AD. The calcium-sensing receptor and the parathyroid: past, present, future. Front physiol 2016;15;7:563, Roszko KL, Bi RD, Mannstadt M. Autosomal dominant hypocalcemia (hypoparathyroidism) types 1 and 2. Front Physiol. 2016;18(7):458.
   Google Scholar
• Marcucci G, Della Pepa G, Brandi ML. Natpara for the treatment of hypoparathyroidism. Expert Opin Biol Ther. 2016;16:1417–1424.
   PubMed Web of Science ®Google Scholar
• Sikjaer T, Rejnmark L, Rolighed L, et al. The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26:2358–2370.
   PubMed Web of Science ®Google Scholar
• Rubin MR, Sliney J Jr, McMahon DJ, et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21:1927–1934.
   PubMed Web of Science ®Google Scholar
• Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98:137–144.
   PubMed Web of Science ®Google Scholar
• Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double blind, placebo-controlled, randomized, phase III study. Lancet. 2013;1:275–283.
   PubMed Web of Science ®Google Scholar
• Lakatos P, Bajnok L, Lagast H, et al. An open-label extension study of parathyroid hormone rhPTH(1-84) in adults with hypoparathyroidism. Endocr Pract. 2016;22:523–532.
   PubMed Web of Science ®Google Scholar
• Rubin MR, Cusano NE, Fan WW, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101:2742–2750.
   PubMed Web of Science ®Google Scholar
• Cusano NE, Rubin MR, McMahon DJ, et al. PTH (1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99:3691–3694.
   Web of Science ®Google Scholar
• Sikjaer T, Rolighed L, Hess A, et al. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25:1717–1726.
   PubMed Web of Science ®Google Scholar
• Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26:2727–2736.
   PubMed Web of Science ®Google Scholar
• US FDA. Natpara (parathyroid hormone) for injection: US prescribing information. 2015. http://www.fda.gov/. [Last accessed 22 June 2015]
   Google Scholar
• Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. Jama. 1996;276:631–636.
   PubMed Web of Science ®Google Scholar
• Winer KK, Yanovski JA, Sarani B, et al. A randomized, crossover trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83:3480–3486.
   PubMed Web of Science ®Google Scholar
• Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88:4214–4220.
   PubMed Web of Science ®Google Scholar
• Winer KK, Sinaii N, Reynolds J, et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95:2680–2688.
   PubMed Web of Science ®Google Scholar
• Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:391–399.
   PubMed Web of Science ®Google Scholar
• Winer KK, Fulton K. Culter PA and cutler g. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr. 2014;165:556–563.
   PubMed Web of Science ®Google Scholar
• Samuels MH, Veldhuis J, Cawley C, et al. Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab. 1993;77:399–403.
   PubMed Web of Science ®Google Scholar
• Santonati A, Palermo A, Maddaloni E, et al. PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2015;100:3590–3597.
   PubMed Web of Science ®Google Scholar
• data available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021318s012lbl.pdf
   Google Scholar
• Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol. 2006;34:929–940.
   PubMed Web of Science ®Google Scholar
• Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27:2419–2428.
   PubMed Web of Science ®Google Scholar
• Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429–2437.
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9–17.
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346–3355.
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146:326–339.
   PubMed Web of Science ®Google Scholar
• Underbjerg L, Sikjaer T, Mosekilde L, et al. Postsurgical hypoparathyroidism – risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29:2504‐2510.
   PubMed Web of Science ®Google Scholar
• Chawla H, Saha S, Kandaswamy D, et al. Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long term follow-up. J Clin Endocrinol Metab. 2017;1:251–258.
   Google Scholar
• Sikjaer T, Rejnmark L, Thomsen JS, et al. Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study. J Bone Miner Res. 2012;27:781–788.
   PubMed Web of Science ®Google Scholar